stockrowTravere Therapeutics, Inc.
TVTX Healthcare Biotechnology
Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024.
- Revenue
- +36.2%
- EPS
- −290.7%
- Free cash flow
- +6,379.8%
- Total debt
- +93.8%
Quarter to September 2026, against a year earlier
Follow TVTX
Alert me
Travere Therapeutics, Inc. (TVTX) EPS (diluted)
Travere Therapeutics, Inc.'s EPS (diluted) for fiscal 2025 was −$0.29, compared with −$4.08 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$1.29. Over the past ten years it has ranged from −$4.37 (fiscal 2022) to $3.17 (fiscal 2015); the current reading is higher than 91% of that period. Travere Therapeutics, Inc. ranks 251st of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$0.29 | — |
| FY2024 | −$4.08 | — |
| FY2023 | −$1.50 | — |
| FY2022 | −$4.37 | — |
| FY2021 | −$3.01 | — |
| FY2020 | −$3.56 | — |
| FY2019 | −$3.46 | — |
| FY2018 | −$2.54 | — |
| FY2017 | −$1.54 | — |
| FY2016 | −$1.29 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.55 | — |
| Jun 2026 | −$0.37 | — |
| Mar 2026 | −$0.40 | — |
| Dec 2025 | $0.03 | (89.29%) |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | $8.19 |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$0.50 |
| ERAS Erasca, Inc. compare | −$0.95 |
| TVTX Travere Therapeutics, Inc. | −$1.29 |
| COGT Cogent Biosciences, Inc. compare | −$2.16 |
| DFTX Definium Therapeutics, Inc. compare | −$3.43 |
| DNTH Dianthus Therapeutics, Inc. compare | −$3.99 |
| CRSP CRISPR Therapeutics AG compare | −$4.74 |
| MANE Veradermics Incorporated compare | −$45.88 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on TVTX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement